Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

The 23rd Annual Conference
Chinese Biopharmaceutical Association

The Bridge of US-China Biopharmaceuticals

Saturday, June 9th, 2018
One MedImmune Way, Gaithersburg, Maryland 20878
A Letter from the CBA President

Dear CBA Members and Friends:

I am greatly honored to welcome all of you to the 23rd Chinese Biopharmaceutical Association in the USA (CBA-USA) Annual Conference. CBA hosts this conference on June 9, 2018 with support from MedImmune, a member of the AstraZeneca group, which provides the state-of-the-art conference facility on its beautiful campus.

It has been more than two decades of robust growth for the CBA. Twenty-three years ago, we were a tiny group of young scientists working in the USA with ties to China, but we had a big vision: create a platform for collaboration in life sciences and the biopharmaceutical industry. Thanks to the dedication of our members, CBA has grown into a truly global organization with a strong and growing reputation. This conference will serve to reinforce and expand CBA’s commitment to fostering greater global collaboration and new partnerships between China and the USA in the biotech and pharmaceutical arenas.

It has been my honor to serve as the chair of the 23rd Annual Conference Organizing Committee. The theme of this year’s conference is “Bridging Innovations, Entrepreneurs, and Opportunities to Advance Global Biopharmaceutical Development.” We are very fortunate and honored to have more than 25 distinguished leaders speak at our conference. Our program includes keynote speeches of CBA Brilliant Achievement Award recipients and seven sessions that bring together elite minds from around the world to share their insights on the latest progress in global biopharmaceutical development.

CBA has received very generous support this year from our sponsors, which include biopharmaceutical companies, contract research organizations (CROs), biotech service providers, and medical device companies operating in China, the USA, and Canada, as well as the Department of Commerce of Maryland. On behalf of CBA, I would like to sincerely thank all of our sponsors for their strong commitment and contributions to the success of this conference.

As the chair of this year’s Conference Organizing Committee, I would like to express my profound gratitude to all the committee members and the many CBA members who have worked so diligently to organize every detail to ensure that each of you will greatly enjoy this year’s event. I am enormously grateful for your commitment and dedication to this year’s conference.

Sincerely,

Frank Li L, M.D., Ph.D.
President-Elect, CBA-USA
Chair, the 23rd CBA Annual Conference Organizing Committee
CBA History and Accomplishments 1995 – 2018

The Chinese Biopharmaceutical Association-USA (CBA-USA) (www.cba-usa.org) is one of the largest Chinese American professional associations in the US. CBA was founded in 1995 by a group of Chinese American biopharmaceutical professionals as a non-political and non-profit organization headquartered in the Washington DC area.

The mission of CBA is to promote communication and collaboration among biopharmaceutical professionals and to foster business collaborations among different countries and regions, especially between the US and China. CBA has an excellent reputation both in China and the US for developing and enhancing friendship and cooperation in the biopharmaceutical and life sciences industries. Our efforts have been applauded by industry executives and prominent leaders from both the US and China. The former China Minister of Health, Dr. Zhu Chen, former US Deputy Secretary of Labor, Samuel Tingping Moi, former Chinese Ambassadors to the US, Weizhong Zhou and Deqiu Li, and dozens of prominent leaders from academia, industry and government have attended and addressed at CBA’s events. A number of prestigious scientific journals, including Nature, Science, and Bioprocess International, have reported on the CBA, its event, as well as its members.

Since its establishment, CBA has stayed true to its mission in bridging the biopharmaceutical industry between the US and China. Its signature event, the CBA annual conference, which has been successfully held in the US or in China for 22 years, has served as an effective platform that brought together the elite scientific minds, successful entrepreneurs, and government agencies in the pharmaceutical and biotechnology areas. Some of the key topics at the past CBA annual conferences included:

- Cutting edge sciences and technologies in the development of medicines
- Commercialization and globalization of biopharmaceutical development through partnerships
- Regulatory perspectives of pharmaceutical development

In addition to the annual conferences, CBA has hosted and co-hosted with American and Chinese professionals and industrial organizations in biopharmaceutical areas a large number of workshops and seminars focusing on local and international hot topics, and cutting edge research and technology discoveries. The most recent events include:

- The 9th Human Vaccine Industry Summit 2017, Qingdao, China
- Shanghai BioPharm Forum 2017, Shanghai, China
- Precision Medicine and Immun-Oncology China 2017, Shanghai, China
- Asia Pharma R&D Summit 2017, Shanghai, China

In the past 23 years, CBA has also served as an incubator for talents and entrepreneurs, and a place for professional networking and development. Many former CBA presidents and board members are now established industry leaders in the US and China, such as Dr. Guoliang Yu, Chairman of CrownBio; Dr. Dayun Yang, Chairman and CEO of Ascentage; Dr. Dan Zhang, Chairman of Fountain Medical Development; Dr. Patrick Lu, Chairman and CEO of Simmacs; Dr. Dong Xie, Chairman and COO of Frontier Biotechnologies; Dr. Yingxian Xiao, CEO of Shanghai Furen Medicine; Dr. Sujuan Ba, President and COO of National Foundation for Cancer Research; and biotech entrepreneur stars such as Dr. Ping Chen and Dr. Zijing Wu.

Since 2016, CBA has started to organize bimonthly workshops to provide opportunities for sharing expertise and discussing latest topics by experts. CBA also helps members with their career development in the biopharmaceutical industry. Each of these events attracted hundreds of medical, clinical and pharmaceutical students and professionals who were seeking new or advanced career opportunities.

In 2018, CBA launched new initiatives to form multiple small study groups to discuss innovative trends in the biopharmaceutical industry. These are venues for members to share expertise and deepen their knowledge. The Biomarker and Diagnostics Study Group, composed of 19 CBA active members, kicked off the series of activities on May 06, 2018. Other study groups covering other latest trends in drug development are in progress.

CBA is also a place where Chinese American pharmaceutical professionals celebrate. Over the years, the CBA Chinese New Year Gala and summer picnics provided relaxing and fun opportunities for CBA members to connect and celebrate. CBA just celebrated its 23rd anniversary at its 2018 Chinese New Year Gala. The success of the organization is attributed to the active involvement of members around the US who strongly believe in its mission. Today, the global biopharmaceutical and healthcare industry continues to evolve and grow, particularly in China and the Asia Pacific area. The CBA members are ready to rise to the challenges ahead.

Through the persistent efforts of the CBA’s strong leadership, its devoted members and volunteers, its sponsors and supporters in the past 23 years, CBA has become a well-recognized Chinese American professional organization with more than 8000 members in the US, China, and the rest of the world.

CBA Sponsors & Donations, please mail to:
P. O. Box 61362
Potomac, MD 20859-1362

CBA Membership Registration:
TABLE OF CONTENTS

MEDIIMMUNE MAP .................................................. 2
CBA WELCOME ....................................................... 3
CBA INTRODUCTION .............................................. 4
TABLE OF CONTENTS ............................................. 7
CBA PRESIDENTS ................................................... 7
CONFERENCE AGENDA ......................................... 8
BRILLIANT ACHIEVEMENT AWARD PRESENTATIONS ....... 11

BIOGRAPHY BY SESSION

SPECIAL PRESENTATION: CREATING A PHARMACEUTICAL INNOVATION ECOSYSTEM .......... 15
GLOBAL DRUG DEVELOPMENT: ICH & ROLE OF CHINA ....................... 16
ENTREPRENEUR INCUBATORS AND COLLABORATION ............... 18
ADVANCED TRANSLATIONAL MEDICINE .................................. 20
ARTIFICIAL INTELLIGENCE AND BIG DATA IN BIOPHARMACEUTICAL DEVELOPMENT .......... 21
REAL WORLD EVIDENCE MEDICINE IN BIOPHARMACEUTICAL DEVELOPMENT .......... 22
ENTREPRENEURS AND INVESTORS .................................. 23
CEO ROUNDTABLE .................................................. 26

2017-2018 ACTIVITIES ............................................ 28
UPCOMING ACTIVITIES ........................................... 29
CBA PAST 10-YEAR AWARD RECIPIENTS .......... 30
CBA PAST PRESIDENTS & CONFERENCES .................. 31
CBA BOARD MEMBERS & ORGANIZING COMMITTEE .............. 32
SPONSOR HIGHLIGHTS ............................................ 51
SCHEDULE AT A GLANCE .......................................... 57
### CONFERENCE AGENDA - MORNING SESSION

<table>
<thead>
<tr>
<th>TIME</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30-8:30</td>
<td>Registration and Continental Breakfast; Exhibition Booth Setup</td>
<td>Hotel Ballroom</td>
</tr>
<tr>
<td>8:30-8:35</td>
<td>Welcome to CBA 23rd Annual Conference</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>8:35-8:50</td>
<td>Opening Remarks</td>
<td>Ballroom A</td>
</tr>
<tr>
<td>9:20-9:25</td>
<td>创建, 创业, 创机遇, 迎接全球生物制药新时代</td>
<td>Auditorium</td>
</tr>
<tr>
<td>9:25-9:50</td>
<td>CBA Brilliant Achievement Award Presentation: Clinical Safety Statistics, Merck &amp; Co</td>
<td>Auditorium</td>
</tr>
<tr>
<td>9:50-9:55</td>
<td>创建, 创业, 创机遇, 迎接全球生物制药新时代</td>
<td>Auditorium</td>
</tr>
<tr>
<td>9:55-10:00</td>
<td>Coffee Break</td>
<td>Hotel Ballroom</td>
</tr>
<tr>
<td>10:00-10:05</td>
<td>Introduction of CBA Brilliant Achievement Award: Yong Jun Liu, Ph.D., Ph.D.</td>
<td>Auditorium</td>
</tr>
<tr>
<td>10:05-10:30</td>
<td>CBA Brilliant Achievement Award Presentation: Follow the Science and Capture the Opportunity</td>
<td>Auditorium</td>
</tr>
<tr>
<td>10:35-11:00</td>
<td>Introduction of CBA Brilliant Achievement Award: Laurence J.N. Cooper, M.D., Ph.D.</td>
<td>Auditorium</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>Panel Discussion</td>
<td>Auditorium</td>
</tr>
<tr>
<td>11:15-11:35</td>
<td>Global Drug Development: ICH and Role of China</td>
<td>Auditorium</td>
</tr>
<tr>
<td>11:35-12:00</td>
<td>Issues in Multiregional Clinical Trials</td>
<td>Auditorium</td>
</tr>
<tr>
<td>12:00-12:25</td>
<td>CBA’s Regulatory Reform: Opportunities and Challenges</td>
<td>Auditorium</td>
</tr>
<tr>
<td>12:25-12:35</td>
<td>Panel Discussion</td>
<td>Auditorium</td>
</tr>
<tr>
<td>12:35-1:30</td>
<td>Lunch</td>
<td>Hotel Ballroom</td>
</tr>
</tbody>
</table>

### CONFERENCE AGENDA - AFTERNOON SESSION

<table>
<thead>
<tr>
<th>TIME</th>
<th>Parallel Sessions A</th>
<th>Time</th>
<th>Parallel Sessions B</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30-1:30</td>
<td>Introduction of CBA Brilliant Achievement Award: Sujuan Ba, Ph.D.</td>
<td>1:30-2:30</td>
<td>Advanced Translational Medicine - SCBA - Multi-Purpose Room</td>
</tr>
<tr>
<td>1:30-1:45</td>
<td>Incubators in Montgomery County, Maryland</td>
<td>1:30-1:45</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>1:45-2:05</td>
<td>Incubators in China</td>
<td>1:45-2:05</td>
<td>Ascentage Pharma</td>
</tr>
<tr>
<td>2:05-2:15</td>
<td>Maryland Resources for Business Growth</td>
<td>2:05-2:15</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>2:25-2:30</td>
<td>Panel Discussion</td>
<td>2:25-2:30</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>2:30-3:30</td>
<td>Artificial Intelligence and Big Data in Biopharmaceutical Development - Auditorium</td>
<td>2:30-3:30</td>
<td>Real World Evidence Medicine in Biopharmaceutical Development - Multi-Purpose Room</td>
</tr>
<tr>
<td>2:30-2:50</td>
<td>Application of Deep Learning in Drug Discovery</td>
<td>2:30-2:50</td>
<td>Information Exchange and Data Transformation (INFORMED)</td>
</tr>
<tr>
<td>2:50-3:10</td>
<td>Burn the Haystack: Finding the Needle in Clinical Notes &amp; Genomics at Scale</td>
<td>2:50-3:10</td>
<td>Realizing the Potential of Real World Data and Evidence</td>
</tr>
<tr>
<td>3:10-3:30</td>
<td>Deep Learning Convolutional Neural Networks Techniques &amp; Their Applications in Biomedical Sciences - A Successful Example in Lung Imaging</td>
<td>3:10-3:30</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>3:30-3:45</td>
<td>Advanced Translational Medicine - SCBA - Multi-Purpose Room</td>
<td>3:30-3:45</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>3:45-4:00</td>
<td>Artificial Intelligence and Big Data in Biopharmaceutical Development - Auditorium</td>
<td>3:45-4:00</td>
<td>Information Exchange and Data Transformation (INFORMED)</td>
</tr>
<tr>
<td>4:00-4:15</td>
<td>Application of Deep Learning in Drug Discovery</td>
<td>4:00-4:15</td>
<td>Realizing the Potential of Real World Data and Evidence</td>
</tr>
<tr>
<td>4:15-4:30</td>
<td>Burn the Haystack: Finding the Needle in Clinical Notes &amp; Genomics at Scale</td>
<td>4:15-4:30</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>4:30-4:45</td>
<td>Deep Learning Convolutional Neural Networks Techniques &amp; Their Applications in Biomedical Sciences - A Successful Example in Lung Imaging</td>
<td>4:30-4:45</td>
<td>AstraZeneca</td>
</tr>
</tbody>
</table>
CONFERENCE AGENDA - AFTERNOON SESSION

5:00-6:30

CEO Roundtable
Co-Chairs: Yanyang Xing, M.D., Ph.D., Immediate Past President of CBA
           Daqian Yang, M.D., Ph.D., Former President of CBA
           Co-Founder, Chairman & CEO of Ascentage Pharma

- Christopher Adams, Ph.D., Andarix Pharmaceuticals
- Xiaobin Qiu, M.D., PhD, Managing Director of CR-CP
- Lielong Chen, M.D., PhD. Profile & Chairman of Frontier Biotech
- Yingjian Xiao, Ph.D., CEO of Shanghai Furen Medicine R&D Co., Ltd.
- Dajun Yang, M.D., Ph.D., Co-Founder, Chairman & CEO of Ascentage Pharma
- Matt Pietras, M.S., MBA, Head of Finance-Viela Bio
- Dan Zhang, M.D., MPH, Chairman of Fountain Medical Development
- Xin Zhang, Ph.D., Vice President & Global Head of DMPK, Bioanalysis & Abgent, WuXi AppTec
- Xianhao Xiang, CEO, Shanghai Naxil Biotechnology Engineering Co., Ltd.
- Youbin Qiu, General Manager of Jiangsu Huayue Medical Device Supply Chain Co.

6:30-7:15

Reception

7:15-8:45

Dinner Banquet
Master of Ceremony (MC): Patrick Lu, Ph.D. and Yali Fu, Ph.D.

8:40-8:45

Concluding Remarks
Frank Li Li, M.D., Ph.D., CBA President (2018-2019)

9:00

Conference / Event Concludes
Presentation Title: 1971-2018: Personal Reflections on Nixon's War on Cancer

Richard Pazdur, M.D. is the director of the FDA’s Oncology Center of Excellence (OCE), which leverages the combined skills of the FDA’s regulatory scientists and reviewers with expertise in drugs, biologics and devices to expedite the development of novel cancer products. Pazdur previously served as the director of the Office of Hematology and Oncology Products (OHOP) in the FDA’s Center for Drug Evaluation and Research since 2005 and will continue to serve in OHOP as acting director. Pazdur was the director of the Division of Oncology Drug Products from September 1999 to May 2005. Prior to joining the FDA, Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center from 1988 to 1999. During that time Pazdur held administrative positions of assistant vice president for academic affairs, associate director of clinical trials administration (Division of Medicine) and director of educational programs (Division of Medicine). Pazdur served on the faculty of Wayne State University, Detroit, Michigan from 1982 to 1988.

Pazdur received his bachelor’s degree from Northwestern University (Evanston, Illinois), his M.D. from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke’s Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.

Pazdur has published more than 400 articles, book chapters and abstracts. Pazdur has received numerous prestigious awards and honors, including “one of the 50 World’s Greatest Leaders” from Fortune magazine (2015), the Distinguished Public Service Award from the American Association for Cancer Research (2015), the Service Recognition Award from the American Society of Clinical Oncology (ASCO) (2009), the Public Service Award by ASCO (2013), the Public Service Leadership Award from the National Coalition for Cancer Survivorship (2015), the Face of Hope Award from the LUNGevity Foundation (2015), and “The One Hundred” list from Massachusetts General Hospital Cancer Center (2016). (2015), the Public Service Leadership Award from the National Coalition for Cancer Survivorship (2015), the Face of Hope Award from the LUNGevity Foundation (2015), and “The One Hundred” list from Massachusetts General Hospital Cancer Center (2016).

Presentation Title: The Genetic Engineering of T Cells: From Bench, to Bedside, to Boardroom

Prior to becoming the Chief Executive Officer of ZIOPHARM in May 2015, Dr. Laurence Cooper was a tenured Professor (early/exceptional promotion) at The University of Texas MD Anderson Cancer Center (MDACC), with joint appointments in the Division of Pediatrics and Department of Immunology. He also served as Section Chief of Cell Therapy at the Children’s Cancer Hospital at MDACC where, as a Visiting Scientist at MDACC, he will continue to lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. Dr. Cooper has co-authored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He is undertaking the first protocols using a new approach to gene therapy based upon the Sleeping Beauty transposon/transposase system and has helped develop clinical-grade artificial antigen presenting cells for numerically expanding and activating lymphocytes. Dr. Cooper obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.
SPECIAL PRESENTATION

CREATING A PHARMACEUTICAL INNOVATION ECOSYSTEM
Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

Presentation Title: Creating a Pharmaceutical Innovation Ecosystem

Dr. Xin Zhang joined WuXi AppTec in September 2013. Prior to joining WuXi, Dr. Zhang worked for Charles River Laboratories, LabCorp (Tandem Labs) and Agilux Laboratories. After earning a degree in physical chemistry from Peking University and working in China for a few years, Dr. Zhang traveled to the US to pursue his graduate career and obtained his Ph.D. in organic chemistry from the University of Iowa. Dr. Zhang completed his postdoc training at Northeastern University, where he focused on new mass spectrometry applications including oligonucleotides, DNA adducts, and proteomics.

Session Chair

SUJUAN BA, PH.D.
President and COO, National Foundation for Cancer Research

Dr. Sujuan Ba serves as the President and COO of the National Foundation for Cancer Research. She is also the founder and CEO of the Asian Fund for Cancer Research. Dr. Ba has served continuously for 13 years as co-Chair of the Prize Selection Committee of the Szent-Györgyi Prize for Progress in Cancer Research.

Dr. Ba co-founded and serves as a founding board member of the Global Coalition for Adaptive Research (GCAR), the organiser body leading the global implementation of GMR-AAGLE, a groundbreaking adaptive clinical trial initiative designed to produce new and better treatments for glioblastoma multiforme. She is also a co-founder of the International Cancer Impact Fund, the former President of the Chinese Biopharmaceutical Association, and serves on the International Consulting Board of the China National Research Center for Translational Medicine (Shanghai). She also sits on the Scientific Advisory Boards of Mediks, Inc. (Fountain Hills, Arizona) and Immunocom Inc. (San Diego).

She was recognized in 2017 by the Chinese Medical Doctor Association for her outstanding contributions to international cooperation and was named one of the “Top 300 Women Leaders in Global Health” in 2015 by the Graduate Institute of International and Development Studies’ Global Health Programme.

Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of
GLOBAL DRUG DEVELOPMENT: ICH AND ROLE OF CHINA

Session Co-chair

Jingyu (Julia) Luan, Ph.D.
Co-Leader, Division of Biometrics
Office of Biostatistics, FDA CDER

Jingyu (Julia) Luan is a CBA board member. She joined the FDA CDER in 2005. Until 2015, she was a reviewer for neurology, cardio-renal, and psychiatry drug products in Division of Biometrics. Since then, she has been a Team Leader in Division of Biometrics. She provides statistical support for generic drug review.

Presentation Title: Issues in Multiregional Clinical Trials

Dr. Aloka Chakravarty is the Acting Director of the Office of Biostatistics in CDER. FDA. Dr. Chakravarty joined CDER in 1992 and brings to her current position considerable experience in CDER. She is an internationally recognized thought leader in multi-regional clinical trials, safety evaluation, surrogate markers and biomarkers in drug development and has presented and published widely on it. Her research interests include MRCTs, surrogate endpoint methodology, biomarkers, interim analysis, meta-analysis, Bayesian methodology, safety evaluation and statistical computing. Dr. Chakravarty served as an Adjunct Faculty in Department of Statistics, Foundation for Advanced Education in the Sciences, National Institutes of Health. Dr. Chakravarty has received numerous awards, including the FDA Award of Merit in 2008 and Dr. Frances O. Kelsey Drug Safety Excellence Award in 2012. Aloka received her Ph.D. in Statistics from Temple University, and Master of Statistics from Indian Statistical Institute. Dr. Chakravarty is a Fellow of the American Statistical Association and an Associate Editor of Statistics in Biomedical Research.

Panelist

Dr. Alaka Chakravarty is the Acting Director of the Office of Biostatistics in CDER, FDA. Dr. Chakravarty joined CDER in 1992 and brings to her current position considerable experience in CDER. She is an internationally recognized thought leader in multi-regional clinical trials, safety evaluation, surrogate markers and biomarkers in drug development and has presented and published widely on it. Her research interests include MRCTs, surrogate endpoint methodology, biomarkers, interim analysis, meta-analysis, Bayesian methodology, safety evaluation and statistical computing. Dr. Chakravarty served as an Adjunct Faculty in Department of Statistics, Foundation for Advanced Education in the Sciences, National Institutes of Health. Dr. Chakravarty has received numerous awards, including the FDA Award of Merit in 2008 and Dr. Frances O. Kelsey Drug Safety Excellence Award in 2012. Aloka received her Ph.D. in Statistics from Temple University, and Master of Statistics from Indian Statistical Institute. Dr. Chakravarty is a Fellow of the American Statistical Association and an Associate Editor of Statistics in Biomedical Research.

Presentation Title: Issues in Multiregional Clinical Trials

Dr. Alaka Chakravarty is the Acting Director of the Office of Biostatistics in CDER, FDA. Dr. Chakravarty joined CDER in 1992 and brings to her current position considerable experience in CDER. She is an internationally recognized thought leader in multi-regional clinical trials, safety evaluation, surrogate markers and biomarkers in drug development and has presented and published widely on it. Her research interests include MRCTs, surrogate endpoint methodology, biomarkers, interim analysis, meta-analysis, Bayesian methodology, safety evaluation and statistical computing. Dr. Chakravarty served as an Adjunct Faculty in Department of Statistics, Foundation for Advanced Education in the Sciences, National Institutes of Health. Dr. Chakravarty has received numerous awards, including the FDA Award of Merit in 2008 and Dr. Frances O. Kelsey Drug Safety Excellence Award in 2012. Aloka received her Ph.D. in Statistics from Temple University, and Master of Statistics from Indian Statistical Institute. Dr. Chakravarty is a Fellow of the American Statistical Association and an Associate Editor of Statistics in Biomedical Research.

Panelist

Dr. Shou-Bai Chao is former president of Chinese Biopharmaceutical Association. He is currently Chief Operations Officer at CardSino Bio. Prior to joining CardSino BIO, Dr. Chao was Senior Vice President at AstraZeneca leading AstraZeneca’s BioVentures business unit to develop Biosimilars and BioBetters for global markets with leading biotech companies in China and other Asian countries.

Panelist

Dr. Gang Wang is former Chief Scientist in the Center for Drug Evaluation (CDE) at China FDA (CNDA). At this position, he is primarily responsible for developing, establishing and implementing the compliance and inspection program in CDE. Prior to joining CDE, Dr. Wang worked at the US FDA for 12 years. More recently, he served as Senior Policy Advisor in the Office of Manufacturing Quality (OMQ), Office of Compliance in CDER. He provides advice on policy, regulation, compliance and international affairs related issues to the senior management in the Office; Assistant Country Director of the FDA China Office in the US Embassy Beijing, responsible for policy analysis, outreach and capacity building in the drug portfolio, and collaboration between US FDA, CNDA, pharmaceutical industry and other stakeholders; Senior Reviewer/Expert Biological/ Lead Inspector of the Office of Compliance and Biologics Quality (OCBIQ) in CBER, responsible for CMC reviews and pre-approval and pre-approval inspections for biologics regulated by CBER. Dr. Wang is a peer-reviewed expert in biologics manufacturing and CGMP, especially in the area of cell and gene therapy product manufacturing, regulation and supervision.

Gang Wang, Ph.D.
Former Chief Scientist, Center for Drug Evaluation (CDE), China FDA (CNDA)

Panelist

Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd, a clinical CRO with 1700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia & USA. Dr. Zhang is a member of ICH ETD Expert Working Group. He is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the CFDA.

Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd, a clinical CRO with 1700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia & USA. Dr. Zhang is a member of ICH ETD Expert Working Group. He is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the CFDA.

Panelist

Dr. William (Bill) Wang is executive director, clinical safety statistics, in the department of Biostatistics and Research Decision Sciences (BARDS), Merck Research Laboratories. He has over 25 years of experience in the pharmaceutical industry, with expertise and research publications in statistical design, analysis, clinical data management and their technology enablement.

Bil Wang, Ph.D., Executive Director, Clinical Safety Statistics, Merck & Co., Inc.

Panelist

Dr. Shou-Bai Chao is former president of Chinese Biopharmaceutical Association. He is currently Chief Operations Officer at CardSino Bio. Prior to joining CardSino BIO, Dr. Chao was Senior Vice President at AstraZeneca leading AstraZeneca’s BioVentures business unit to develop Biosimilars and BioBetters for global markets with leading biotech companies in China and other Asian countries.

Shou-Bai Chao, Ph.D.
Chief Operating Officer, CardSino BIO
Session Chair
Dr. Mao is Co-founder and Senior Vice President of CanSino Biologics Inc. which specializes in the development and commercialization of innovative vaccine products. In October 2017, CanSino Biologics successfully developed an Ebola Virus Disease Vaccine (EOBV), and obtained new drug approval from CFDA. Dr. Mao is Adjunct Professor of Tianjin University of Sciences and Technology and Nankai University. Dr. Mao is currently a Board of Director with Chinese Biopharmaceutical Association (CBA-US) and a member of BayHelix Association.

Presentation Title: Biotech and Montgomery County’s Economy
Lily Qi is Assistant Chief Administrative Officer for economic and workforce development responsible for the County’s overall economic strategies, business-dilemma issues, economic communication and strategic partnerships with key organizations and institutions. She has served County Executive Ike Leggett for eight years in various capacities and led strategic initiatives including privatizing economic development functions; establishing BioHealth Innovation, Inc. to advance research commercialization; developing global partnerships; improving nighttime economy; and developing the Comprehensive Economic Strategy. Lily joined Montgomery County after serving as Vice President of Business Development and Marketing for the Washington, DC Economic Partnership and spokesperson for the DC Department of Insurance, Securities and Banking. A native of Shanghai, China, Lily is also a writer, speaker and trainer on cultural competency and immigrant integration issues. She was featured in the Washington Business Journal, Bethesda Magazine, China Daily, and Asian Fortune for her professional accomplishments and community leadership, which includes encouraging civic and political engagement of immigrant communities and serving as trustee of the Suburban Hospital of Johns Hopkins Medicine, and immediate past chair of the Maryland Governor’s Commission on Asian-American Affairs.

Presentation Title: Incubating Future Innovators and Entrepreneurs in Life Sciences
Mr. Zhi is the Vice General Manager of China Resources Life Science Park Company (CRLSP) and assistant general manager of Strategy Management Department of China Resources Group. He is in charge of the business development, finance, human resources of CRLSP.

JUAN QI
TEDA U.S. Office
Presentation Title: Maryland Resources for Business Growth
Felicia Pullam is the Regional Manager for East Asia for the Office of International Investment and Trade, Maryland Department of Commerce, where she helps Maryland companies export to China, Taiwan, Japan, and South Korea. She also assists foreign companies that are interested in establishing operations in the state. Before joining the Maryland team, Felicia was the Deputy Assistant Secretary for Textiles, Consumer Goods, and Materials at the U.S. Department of Commerce. She also served as the Director of Outreach for SelectUSA, the federal program to promote foreign direct investment (FDI) into the United States. Prior to her federal service, Felicia helped lead trade and FDI for the State of Delaware. She got her start in international affairs in 2000 through the Princeton in Asia program in Guangzhou, and then spent a year as a tutor and translator for Chinese actress Zhang Ziyi. She proceeded to spend nearly a decade in Asia managing APCO Worldwide’s regional Corporate Responsibility and Sustainability practice.

SARAH MILLER
VP and Chief of Staff
Montgomery County Economic Development Corporation, MD
Presentation Title: Supporting Entrepreneurs in a Sustainable Local Economy
Sarah is MCEDC’s Vice President & Chief of Staff. She has worked in community and economic development in Montgomery County and across Pennsylvania for the past 18 years. She has created riverfront parks, supported new firms, kick-started incubators and engaged civic leaders as they reimagined their former industrial towns. Wherever she is, Sarah’s professional goal remains the same — to provide people with access to new economic opportunities.

Previously, Sarah was Special Assistant to the Secretary in the Pennsylvania Department of Community and Economic Development, Capital Projects Manager for the Department of Economic Development in Montgomery County, and spent many years working in Pittsburgh. A graduate of Ohio University, where she studied community health, she also received a master’s degree from Carnegie Mellon University in Public Policy & Management, with a concentration in economic development. Sarah currently serves on the Rockville Planning Commission, the Montgomery County Food Council and also on the incubator committee for Bethesda Green. She lives in Rockville with her husband and son.

Presentation Title: Introduction of Maryland International Incubator
Alex brings 15 years of experience in management consulting, business startups, overseas investment, and healthcare industry. For the past eight years, he has managed complex projects for some of the most innovative companies, including Fortune 500 firms. Unlike many business professionals, Alex brings a strong sciences and technology background to inspire his business solutions. He worked at Ernst & Young Life Sciences Consulting Division (New York City), Mt. Sinai Hospital (New York City), and Zhengzhou Pharmaceuticals (Tianjin, China). He served as a key executive of a nanotechnology startup company. In his own time, Alex serves as a professional interpreter for Chinese hospital presidents and manages their network event with American hospital executives since 2008.

ALEX WANG
Professor
University of Maryland at College Park
Presentation Title: Introduction of Maryland International Incubator
Alex received his Ph.D. from University of Pennsylvania School of Medicine (cell & molecular biology major), and an MBA from University of Notre Dame (consulting major).

Presentation Title: To Advance Global Biopharmaceuticals Development
Mr. Jianing Li is the Chief Representative of TEDA U.S. Office based in Chicago, IL, since August 2006. Before that, Mr. Li worked as Senior Project Manager of TEDA Investment Bureau from 2001 to 2005, and Section chief of TEDA City Development Bureau from 1997 to 2001. Mr. Li has Bachelor degree on Mechanical Engineering from Tsinghua Institute of Industry (1989 to 1993) and Master degree of Finance from Tianjin University of Economics and Finance (from 1997 to 1998). Mr. Li also got his MBA diploma from West Virginia University (from 2005 to 2006). Mr. Li’s current major role is to help the U.S. companies expand their business in China, including direct investment, franchising, seeking partners, outsourcing and marketing. Mr. Li also helps many Chinese companies to make investments in the U.S.

FELICIA PULLAM
Regional Manager, East Asia & Investment Team Lead
Office of International Investment & Trade, MD Department of Commerce
Presentation Title: Supporting Entrepreneurs in a Sustainable Local Economy
Felicia Pullam is the Regional Manager for East Asia for the Office of International Investment and Trade, Maryland Department of Commerce, where she helps Maryland companies export to China, Taiwan, Japan, and South Korea. She also assists foreign companies that are interested in establishing operations in the state. Before joining the Maryland team, Felicia was the Deputy Assistant Secretary for Textiles, Consumer Goods, and Materials at the U.S. Department of Commerce. She also served as the Director of Outreach for SelectUSA, the federal program to promote foreign direct investment (FDI) into the United States. Prior to her federal service, Felicia helped lead trade and FDI for the State of Delaware. She got her start in international affairs in 2000 through the Princeton in Asia program in Guangzhou, and then spent a year as a tutor and translator for Chinese actress Zhang Ziyi. She proceeded to spend nearly a decade in Asia managing APCO Worldwide’s regional Corporate Responsibility and Sustainability practice.

Sarah is MCEDC’s Vice President & Chief of Staff. She has worked in community and economic development in Montgomery County and across Pennsylvania for the past 18 years. She has created riverfront parks, supported new firms, kick-started incubators and engaged civic leaders as they reimagined their former industrial towns. Wherever she is, Sarah’s professional goal remains the same — to provide people with access to new economic opportunities.

Previously, Sarah was Special Assistant to the Secretary in the Pennsylvania Department of Community and Economic Development, Capital Projects Manager for the Department of Economic Development in Montgomery County, and spent many years working in Pittsburgh. A graduate of Ohio University, where she studied community health, she also received a master’s degree from Carnegie Mellon University in Public Policy & Management, with a concentration in economic development. Sarah currently serves on the Rockville Planning Commission, the Montgomery County Food Council and also on the incubator committee for Bethesda Green. She lives in Rockville with her husband and son.

Presentation Title: Introduction of Maryland International Incubator
Alex brings 15 years of experience in management consulting, business startups, overseas investment, and healthcare industry. For the past eight years, he has managed complex projects for some of the most innovative companies, including Fortune 500 firms. Unlike many business professionals, Alex brings a strong sciences and technology background to inspire his business solutions. He worked at Ernst & Young Life Sciences Consulting Division (New York City), Mt. Sinai Hospital (New York City), and Zhengzhou Pharmaceuticals (Tianjin, China). He served as a key executive of a nanotechnology startup company. In his own time, Alex serves as a professional interpreter for Chinese hospital presidents and manages their network event with American hospital executives since 2008.

ALEX WANG
Professor
University of Maryland at College Park
Presentation Title: Introduction of Maryland International Incubator
Alex received his Ph.D. from University of Pennsylvania School of Medicine (cell & molecular biology major), and an MBA from University of Notre Dame (consulting major).
Presentation Title: Gut Microbiome Controls Liver Tumor Growth via Bile Acid-regulated NKT Cells

Chi Ma M.D., Ph.D. received his medical degree at Jhing medical college in Shandong, China in 2001. He did his PhD training (2001-2007) in Sun Yat-sen University working on signal transduction, following by 3-year postdoctoral fellowship at University of Texas at Dallas. In 2011, Dr. Chi Ma moved to NIH and joined the laboratory of Tim Greten and started his work in the field of tumor immunology as a postdoctoral fellow. He found that the nonalcoholic fatty liver disease causes selective CD4+ T cell loss and impairs live anti-tumor surveillance (Nature 2016). His recent work discovered that gut commensal bacteria can use bile acids as messenger to regular liver anti-tumor immunity thus modulate liver tumor development (Science 2018). In 2016 Chi Ma was promoted as staff scientist.

Presentation Title: T Regulatory Cells for Immunotherapy to Autimmune and Cancer

Dr. Chen is an internationally recognized immunologist at NDBRC, NIH. His research focuses on elucidating mechanisms of T-cell immunity and tolerance and manipulating T-cell immunity versus tolerance in animal models to understand the pathogenesis of and develop immunotherapy for autoimmune and infectious diseases. Dr. Chen is the first who discovered that TGF-beta induces Foxp3 gene in naive CD4+ T cells and converts them into regulatory T cells (Treg). This finding was praised by NIH Intramural Director Dr. Michael Gottesman as a "revolution" and has been cited for more than 4500 times and ranked as the 3rd of 50 most cited papers published in J. Exp. Med. Dr. Chen has also discovered a way to induce autotransgene-specific regulatory T cells in vivo after the animals were developed diseases in experimental models of autoimmunity including EAE, type 1 diabetes and rheumatoid arthritis, which opens a way to develop immunotherapy for human autoimmune diseases and cancer. The discovery has been commented by Science and covered by several news agencies including Xinhua News. Most recently, Dr. Chen has discovered that D-mannose induces generation of regulatory T cells and suppresses autoimmune diabetes and lung inflammation. Dr. Chen has published more than 100 peer-reviewed articles in internationally prestigious journals including Nature, Nature Medicine, Nature Immunology, Immunity, J. Exp. Med.,PNAS, Science Translational Medicine, Cell Stem Cell, etc., and been invited to speak at many international meetings and universities in the world.

Dr. Chen received many honors and awards, including the Scientific Achievement Award from the NH-Asian and Pacific Islander American Organization and the Wang Ying-Lai Memorial Lecturer. In addition to his scientific activities, Dr. Chen was also the elected president of the Society of Chinese Biologists at America (SCBA) Washington DC-Baltimore Chapter in 2015.
REAL WORLD EVIDENCE MEDICINE IN BIOPHARMACEUTICAL DEVELOPMENT

Session Chair

Dr. Zhai is Chief Medical Officer at Ascentage Pharma, responsible for pre-clinical and clinical development of all company’s potential drugs. She has more than 25 years of experience in cancer research and new drug development in multiple therapeutic areas including cancer, cardiovascular, metabolic diseases, autoimmune diseases and immunotherapy. Dr. Zhai served as President of the Chinese Biopharmaceutical Association-USA (CBA) in 2009 – 2010.

Presentation Title: Information Exchange and Data Transformation (INFORMED)

Dr. Sean Khooz is Acting Associate Director at the FDAs Oncology Center of Excellence, and he is the founding director of Information Exchange and Data Transformation (INFORMED), an incubator for collaborative regulatory science re-ware focused on supporting innovations that enhance the agency’s mission to promote and protect public health. INFORMED is expanding organizational and technical infrastructure for big data analytics and examining modern approaches in evidence generation to support regulatory decisions.

Previously, Khooz was in private practice in New York City, an attending physician at St. Vincent’s Hospital in Manhattan and an entrepreneur specializing in building health information technology systems with virtual patient management and point-of-care data visualization and analytics capabilities. Khooz received the 2017 Charles A. Sanders Life Sciences Award (accepted on behalf of the FDA) at the 2017 FDA Commissioner’s Group Award for the Naloxone App Challenge, and the 2004 Abraham Lissner Award in biostatistics and advanced analytics.

Presentation Title: Realizing the Potential of Real World Data and Evidence

Iksha Herr joined AscentaZeneca in January 2017 and in her role as the Real World Evidence Data & Analytics Director, develops and executes Real World data, technology, and analytics related strategic projects. Prior to joining AscentaZeneca, Iksha led real-world data and analytics projects for pharmaceutical / biotechnology companies and management consulting projects for Booz Allen Hamilton. Her work at Booz Allen Hamilton focused on providing strategic roadmaps to federal government healthcare agencies using real world data and evidence, leveraging Big Data technology and platforms.

Iksha received a Bachelor’s degree in Polymer Engineering from Pune University in India and a Master of Science degree in Computer Science from New Jersey Institute of Technology, New Jersey.

Presentation Title: Realizing the Potential of Real World Data and Evidence

Dr. Wang has a comprehensive medical background and extensive research experience. He received Bachelor of medicine, Master of pathology and Doctor of surgery (tutored by Academician Wu Mengchao), and completed a postdoctoral study of cell biology in the United States. Dr. Sun has been engaged in oncology and immunology for 30 years. He worked as a Professor, Doctoral Tutor in immunology and Director of Immunology Laboratory in the Academy of Military Medical Sciences, a Postdoctoral Scholar and Research Scientist at the Blood Center of Wisconsin, Assistant Research Professor at the State University of New York, Assistant to the Director of Beijing Proteome Research Center (BPRC), Director of International Cooperation Department and Principal Investigator (PI) of Antibody Engineering Laboratory at BPRC. He was also an Assistant to the President of the International Human Liver Proteome Plan, the Sub-committee Chairman of the international Human Liver Proteome Antibody Project and a Standing Council Member of the Chinese Human Proteome Organization. Dr. Sun received funding independently from American Heart Association (AHA), and his research projects were supported by National 973, 863, and NNSF in China. He has 100 publications, including more than 20 peer reviewed papers in JBC, Blood, J and PNAS. He also successfully applied for patent “The hybrydoma cell line and its anti human VEGFR-3 monoclonal antibody (200510277455.1)”. Currently Dr. Sun is the Partner, Partner, Vice-President and Chief Medical Officer at Aestelus Technology Company Group (ATCG) in Suzhou, and responsible for the production, quality control and clinical application of CAR-NK for cancer immunotherapy.

Presentation Title: Immunotherapy for Solid Tumors by Chimeric Antigen Receptor (CAR)-modified Allogeneic Natural Killer (NK) Cells

Dr. Wang has a comprehensive medical background and extensive research experience. He received Bachelor of medicine, Master of pathology and Doctor of surgery (tutored by Academician Wu Mengchao), and completed a postdoctoral study of cell biology in the United States. Dr. Sun has been engaged in oncology and immunology for 30 years. He worked as a Professor, Doctoral Tutor in immunology and Director of Immunology Laboratory in the Academy of Military Medical Sciences, a Postdoctoral Scholar and Research Scientist at the Blood Center of Wisconsin, Assistant Research Professor at the State University of New York, Assistant to the Director of Beijing Proteome Research Center (BPRC), Director of International Cooperation Department and Principal Investigator (PI) of Antibody Engineering Laboratory at BPRC. He was also an Assistant to the President of the International Human Liver Proteome Plan, the Sub-committee Chairman of the international Human Liver Proteome Antibody Project and a Standing Council Member of the Chinese Human Proteome Organization. Dr. Sun received funding independently from American Heart Association (AHA), and his research projects were supported by National 973, 863, and NNSF in China. He has 100 publications, including more than 20 peer reviewed papers in JBC, Blood, J and PNAS. He also successfully applied for patent “The hybrydoma cell line and its anti human VEGFR-3 monoclonal antibody (200510277455.1)”. Currently Dr. Sun is the Partner, Partner, Vice-President and Chief Medical Officer at Aestelus Technology Company Group (ATCG) in Suzhou, and responsible for the production, quality control and clinical application of CAR-NK for cancer immunotherapy.
Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co., Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 14. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds academic positions as the guest professor of Beijing University, Clinical Research Institute and adjunct professor of Indiana University School of Medicine.

Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program” in Hengrui, she built the largest clinical team among China domestic pharma and led the successful conduction of clinical trials in China, USA and Australia.

She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently, Joan joined I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.

Panelist

Dr. Xiaochang Dai is the chief investment officer of Rotating Boulder Fund. The fund has a focus on biopharm sector on both sides of Pacific. He is a leading figure in the Chinese pharmaceutical industry in the past two decades. Dr. Dai received his Ph.D from The Scripps Research Institute and his postdoctoral training from California Institute of Technology. Since his return to China in 1999, Dr. Dai has held a series of executive positions.

Panelist

In recent years, Dr. Dang have been interested in understanding and investing in biopharma after have spent decades working with start-up and established pharmaceutical companies. He is an active learner and reader, researching and analyzing corporations quantitatively and qualitatively. He has been influenced by well known value investors and some hedge fund managers. He is also a successful real estate investor. Dr. Dang earned a Ph.D and Masters degrees in Organic Chemistry. He is an author of numerous technical and non-technical publications. Locally he has been active in volunteering to support sciences, education, and active-living projects and activities. He is a marathoner and ultrarunner.
MATT PIETRAS, MS, MBA

Chairman and CEO, Ascentage

CEO of Shanghai Furen Medicine R&D Co., Ltd.

YINGXIAN XIAO, PH.D.

Founder, Chairman & Chief Scientific Officer, Frontier Pharmaceuticals Co., Ltd.

Dr. Xiao’s research interests are on molecular pharmacology of nicotinic receptors, mechanism of ligand-receptor interactions and developing new CNS therapeutics targeting nicotinic receptors. He has authored and co-authored more than 70 peer-reviewed papers. Dr. Xiao was a founding member of the Chinese Biopharmaceutical Association – USA (CBA) in 1995. He has served as a member of CBA Board of Directors since 1997. Dr. Xiao served as the CBA president from 2003 to 2004. He was the recipient of 2008 CBA Outstanding Service Award.

PANELIST

MATT PIETRAS, MS, MBA

Head of Finance Viela Bio

Panelist

Dr. Yingsong Xiao is the founding CEO of Shanghai Furen Medicine R&D Co., Ltd. and has served as CEO and General Manager of the company since 2005. He received his B.S. in microbiology from Northwestern University and his M.S. in microbiology from Institute of Microbiology, Chinese Academy of Sciences. He studied molecular biology and biotechnology at the University of Maryland at College Park and received a Ph.D. in 1994. After a three-year Post-doctoral fellowship in molecular pharmacology at Georgetown University, working on pharmacological properties of neuronal nicotinic acetylcholine receptors, he joined the faculty of Georgetown University School of Medicine in 1997 and worked in Department of Pharmacology until June 2006. Dr. Xiao’s research interests are on molecular pharmacology of nicotinic receptors, mechanism of ligand-receptor interactions and developing new CNS therapeutics targeting nicotinic receptors. He has authored and co-authored more than 70 peer-reviewed papers. Dr. Xiao was a founding member of the Chinese Biopharmaceutical Association – USA (CBA) in 1995. He has served as a member of CBA Board of Directors since 1997. Dr. Xiao served as the CBA president from 2003 to 2004. He was the recipient of 2008 CBA Outstanding Service Award.

Mr. Xiang co-founded Shanghai Nailii Biotechnology Co., Ltd. in 2003 and was responsible for building-up relationships with high-end international biopharmaceutical companies, research institute and universities. He has participated in the construction of National key projects and enterprises. In 2000, he founded his own company, Shanghai Nailii Biotechnology Co., Ltd., which has now become a biopharmaceutical company providing integrated solutions for biopharmaceutical companies.

Mr. Xiang has more than 15 years of experience in the field of biopharmaceuticals and has specialized in the development of production and quality management systems. He has been awarded numerous patents for his contributions to the industry.

Mr. Xiang has been involved in the development of a new biopharmaceutical product that has received FDA approval and has been marketed worldwide. He has also been involved in the development of a new therapeutic for the treatment of diabetes, which is currently in clinical trials.

Mr. Xiang is a member of the board of directors of several major biopharmaceutical companies and is a recognized expert in the field of biopharmaceuticals. He has published numerous papers and has been a frequent speaker at international conferences.

Mr. Xiang is a graduate of the University of Science and Technology of China and holds a degree in chemical engineering. He has also completed executive programs at Harvard Business School and MIT Sloan School of Management.

Panelist

Mr. Qiu is the general manager of Jiangsu Huayue Medical Device Supply Chain Co., Ltd., which focuses on medical device supply chain management and service. The company is responsible for building comprehensive service platforms for medical device companies.

Mr. Qiu started as Professional Engineer. The strong research and technical background to make him a major Committee in national drug discovery at the ministry of science and technology, and one of the outstanding entrepreneurs in China’s modern pharmaceutical industry.

Mr. Qiu was also the representative of Chinese pharmaceutical companies in MEPCs (Management Committee of Biopharmaceuticals and Biotechnology). He has been highly involved in driving the development of China’s biopharmaceutical industry.

Mr. Qiu has more than 20 years of experience in the biopharmaceutical industry. He has worked for numerous leading companies including..
UPCOMING CBA ACTIVITIES (2018-2019)
SAVE THE DATE

- August 2018 - Workshop
- September 2018 - Autumn Picnic
- October 2018 - Workshop
- January 2019 - Workshop
- February 2019 - Chinese New Year Gala
- April 2019 - Career Development Workshop
- 8-9 June 2019 - the 24th Annual Conference
The CBA Brilliant Achievement Award Recipients

The CBA Brilliant Achievement Award was established in 2003 to honor outstanding individuals who have made seminal contributions to science, technology, or business development in the biopharmaceutical fields, and who has been actively involved in building collaborative efforts internationally to advance medical fields. The Award also aims to promote public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

2017
ROBERT TEMPLÉ, M.D., Deputy Director of Clinical Science, FDA CDER
J. CRAIG VENTER, Ph.D., Executive Chairman, Human Longevity, Inc., Founder, Chairman, and CEO of the J. Craig Venter Institute, Co-Founder, Executive Chairman, and Co-Chief Scientist of Synthetic Genomics Inc.

2016
BHARAT JALJAL, Ph.D., Executive Vice President of AstaZeneica and Head of MedImmune
GE LI, Ph.D., CEO and Chairman of Board of Directors, WuXi AppTec

2015
ZHUI CHEN, Ph.D., Vice-Chairman, 12th Standing Committee of the NPC, Chairman, 15th Chinese Peasants and Workers Democratic Party, Member of Chinese Academy of Sciences, Foreign member of the United States National Academy of Sciences

2014
BARRY K. SHAPLEY, Ph.D., 2011 Nobel Laureate for Chemistry, member of the United States National Academy of Sciences, W M Krock Professor of Chemistry at The Scripps Research Institute

2013
CHEN KAIKAI, Ph.D., Member of Chinese Academy of Sciences Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 2015 CBA Lifetime Achievement Award

2012
QIAOYANG SUN, Ph.D., Chairman, Jiangsu Hengyi Medicine CO., LTD. CBA Outstanding Contribution Award

2011
YANGHUA CHEN, Deputy Director, Guangdong Overseas Chinese Affairs Office, CBA Extraordinary Support Award

2010
JAMES L. HUGHES, Ph.D., Senior Fellow, Hudson Institute

2009
CHEN KAIXIAN, M.D., President of China Medical Society, Member of Chinese Academy of Engineering

2008
ZHONG MAN SHAR, M.D., 华中科技大学特聘中国工程院院士

The CBA Outstanding Service Award Recipients

The CBA Outstanding Service Award was established in 2003 to honor individuals who have made significant contributions to CBA:

2017
PENG CHEN, Ph.D., Founder and CEO of Anju Biomed Inc.

2016
RICHARD ZHAO, Ph.D., Professor, University of Maryland School of Medicine

2015
ZHIFENG LONG, Ph.D., Professor, University of Maryland School of Medicine

2014
YULING LI, Ph.D., Fellow, Process Biochemistry, MedImmune

2013
YIFAN ZHAI, Ph.D., Associate professor, Georgetown University School of Medicine

2012
RICHARD ZHAO, Ph.D., President and CEO, Personal Diagnostix

2011
PING CHENG, Ph.D., Executive Chairman, MedImmune

2010
JIAN NI, Ph.D., Professor, University of Maryland School of Medicine

2009
DAN ZHANG, President, Sun-Hoffman Consulting

2008
JIE YIN, President, China Medical Sciences Research Park Corporation, University of Maryland

2007
YIFAN ZHAI, Ph.D., Associate professor, Georgetown University School of Medicine

2006
ROXANNE DUAN, Ph.D., Associate professor, Georgetown University School of Medicine

2005
GUOLIANG YU, Ph.D., Associate professor, Georgetown University School of Medicine

2004
JIE YIN, President, China Medical Sciences Research Park Corporation, University of Maryland

2003
JAMES L. HUGHES, Ph.D., Senior Fellow, Hudson Institute

2002
JIAN NI, Ph.D., Professor, University of Maryland School of Medicine

2001
YIFAN ZHAI, Ph.D., Associate professor, Georgetown University School of Medicine

2000
JIE YIN, President, China Medical Sciences Research Park Corporation, University of Maryland

1999
SUN LU, Ph.D., Associate professor, Georgetown University School of Medicine

1998
ZHIFENG LONG, Ph.D., Professor, University of Maryland School of Medicine

1997
GE LI, Ph.D., Fellow, Process Biochemistry, MedImmune

1996
GUOLIANG YU, Ph.D., Associate professor, Georgetown University School of Medicine
CBA BOARD OR DIRECTORS & ORGANIZING COMMITTEE

CBA Board of Directors

George Chang
Shou-Bai Chao
Ping Chen
Steve Chen
Zhennia Chen
Yali Fu
Xu-Rong Jiang
Feiyan Jin
Alex Lai
Shoupeng Lai
Zhileong Long
Xiaobin Lu
Helen Mao
Jian Ni
Linda Powers
Peter Qian
Edward Wang
Ziping Wei
Jean Xiao
Yingqian Xiao
Qiao Yu
Monica Zhang
Richard Zhao
Frank Li Li
Dong Shen
Jingyu (Julia) Luan
Chuanhua (Julia) Xing
Yuling Wu
John Li
Jincheng Wu

The Organizing Committee of CBA 23rd Annual Conference

Chairman: Frank Li Li

Sujuan Ba
Shoubai Chao
Yali Fu
George Chang
Jack Che
Yan Guo
Yixing Han
Xurong Jiang
Feiyan Jin
Alex Lai
Kevin Li
Jenny Li
Yuling Li
Hang Lu
Xiaobin Lu
Patrick Lu
Julia Luan
Helen Mao
Peter Qian
Dong Shen
Lin Sun
Victoria Sun
Xiangping Wang
Jincheng Wu
Yuling Li
Yuling Wu
Julia Xing*
Vivian Xu
Judy Yu*
Alice Zhang
Limin Zhang
Xuejuan Julie Zhang
Yuling Wu
John Li
Jincheng Wu

Global Platform. One Vision.

Small Molecule Drug R&D and Manufacturing
Biologics R&D and Manufacturing
Cell Therapy and Gene Therapy
Medical Device Testing
Genomics and Molecular Diagnostics

WuXi’s Vision

To become the most comprehensive capability and technology platform in the global pharmaceutical and healthcare industry to fulfill the dream that “every drug can be made and every disease can be treated”.

*Group Lead
**Company Overview**

Hisun is a fully integrated pharmaceutical company. We focus on providing a broad range of products and services for the benefit of all who use them. Our products are manufactured to the highest standards for the overall health and wellness of our patients. We focus our research on conditions that affect people around the world while continuing to invest in broadening our technology and product portfolio.

We apply our breadth of technologies, skilled workforce, state-of-the-art facilities while leveraging a cost competitive base for the benefit of our clients and partners. Our facilities have been inspected by local and international regulatory agencies, including US FDA, EMA and many other authorities.

**Humane-oriented, innovating, self-motivating, united, natural” (HISUN)**

**Now We Are Recruiting…**

**Biomedical related**
- Senior scientist
- Associate Director
- VP of biomedical research

**Quality Assurance related**
- Various positions

Welcome to CBA’s website and our booth for more details
Please also visit our websites for more information
www.hisunpharm.com
www.hisunusa.com

---

60-90% CAR Expression on T cells, fast cell expansion.

- iPS, stem cell transfection and genome editing
- CHO >90%
- Primary neurons

Demo available in US. Send requests to info@celetrix.com
www.celetrix.com
COMPANY OVERVIEW
ASCENTAGE PHARMA is a globally-focused clinical stage biopharmaceutical company developing novel small molecule therapeutics to restore programmed cell death (apoptosis) in cancers, hepatitis B and age-related diseases. The Company is also developing next-generation tyrosine kinase inhibitors.

HIGHLIGHTS
- 4 clinical programs targeting 3 distinct apoptotic pathways: Bcl-2/Bcl-xL, Bcl-2 selective, IAP dimer, MDM2-p53
- 7 novel candidates in Phase III development with First-in-class and Best-in-class potential in US, CHINA and globally
- Unique platform for designing small molecule drugs that inhibit complex protein-protein interactions (PPIs); breakthrough technology based on U of Michigan collaboration
- Global partnership with Unity Biotechnology for therapies to treat aging-related diseases (senolytics)
- $90 million raised to date

PIPELINE

<table>
<thead>
<tr>
<th>Candidate</th>
<th>Mechanism</th>
<th>Indications</th>
<th>IND Enabling</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apog-122</td>
<td>Bcl-2, Bcl-xL, Drp1</td>
<td>Leukemia, Solid Tumors</td>
<td>Phase 1 clinical trial in US</td>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apog-2795</td>
<td>Bcl-2 Releasers</td>
<td>Breast Cancer</td>
<td>US IND submitted</td>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apog-1387</td>
<td>IAP Gainer</td>
<td>Cancer, HIV</td>
<td>Phase 2 &amp; 1/2a clinical trial in US</td>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apog-115</td>
<td>MDM2-p53</td>
<td>Cancer, HIV</td>
<td>Phase 1 dose escalation in US and China</td>
<td>Global</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Kissing Inhibitors (China Market-focused)

<table>
<thead>
<tr>
<th>Candidate</th>
<th>Mechanism</th>
<th>Indications</th>
<th>IND Enabling</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apog-121</td>
<td>PI3K Selective</td>
<td>Leukemia</td>
<td>US Phase 2/3 development</td>
<td>Asia Pacific Inc. Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apog-1261</td>
<td>Beclin-1/Atg5</td>
<td>Cancer, HIV</td>
<td>Phase 1 in China</td>
<td>Global</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apog-9449</td>
<td>FAK</td>
<td>Leukemia, HIV/AIDS</td>
<td>US IND submitted</td>
<td>Global</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Collaborations – Summary Information Provided

Unspecified: Ascantage has a R&D partnership with Unity Biotechnology to co-develop senolytic drugs

COMPLEMENTARY TO I-O & TARGETED THERAPIES

Apoptosis
- Apog-122
- Apog-2795
- Apog-1387
- Apog-115

I-O
- Apog-121
- Apog-1261
- Apog-9449

MDM2
- IAP

GeneKey Biotech Ltd. Co. (GeneKey Biotech), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing up to 200L scale.

Salubris Biotherapeutics, Inc. (SalubrisBio) was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (Salubris Pharmaceuticals). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals’ commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics.

Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$700M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas.

For more information, please visit www.ascentagepharma.com.
FRIDAY, APRIL 6

Makgecpfita
discovery value, realized value

With the most of prescription and best value, it helps high-quality enterprises to link up capital markets.

Escort the high-quality enterprises “step in, pile out”.

FR·MS·SEPIOM·NYNTRODUCT
With the most of prescription and best value, it helps high-quality enterprises to link up capital markets.

Escort the high-quality enterprises “step in, pile out”.

Business Incubator、Business model、Law、Accounting business

Listing Guidance、Financial norms、IPO

Lead Investment、Direct Investment、Introduct early investment

Integrate with international accounting standards、Domestic listed accounting compliance.

To coordinate domestic and overseas financial institutions and exchanges.

Global tax planning and design, implementation of the best tax legal scheme.

Design and establish the internal control system of the enterprise.

Future prediction of the listed subject.

Before the private placement of private equity, help to issue the original private equity.

The price maintenance of the green shoes, the price maintenance after the listing.

Jonathan Chung


Good at Chinese financial standards and international accounting standards; UK GXG sponsor qualification.

Sophia Sun

CEO of chinese zone CBA deputy director and Secretary General of the CBA Office

Overseas asset management companies.

More than 15 years industry experience; Good at international capital operation, Good at enterprise listing and price maintenance.

It aimed to be established an International Biomedical Park by a number of senior industry experts, who are the most professional people

Business Incubation Model International Law, Accounting Investment, Maintenance Price after listing

Listed Counselling、Financial regulation, Global tax planning Connecting business administration, Internal planning and maintenance of foreign relation

Hong Kee Capital Building, 135 Beach Road, Hong Kong.

OCG International Center, The Fourth Tianfu Street, High-tech Zone, Chengdu, China.

TEL:0086-69295235 0086-18628220888

EMAII: sophiasun11@hotmail.com; cba-sc@163.com
PharmEng Technology has been providing quality services to the manufacturers of health care products for over 15 years. In highly regulated industries, there is a need for experienced specialists who can provide solutions in a cost effective and timely manner. PharmEng Technology is a full service consulting firm that specializes in Commissioning & Qualification, Validation, Quality Systems, Regulatory Affairs, Engineering and Training. We provide a wide range of services to the pharmaceutical, biotechnology, medical device and nutraceutical industry. We are a global company and we are here to assist your company with any issue you may be facing.

At PharmEng Technology, we have a highly qualified and dedicated professional team who believes quality plays an integral role in every facet of our activities. Our international presence ensures we are current with regulatory practices and ahead of the emerging trends around the globe. Our staff brings a variety of disciplines to the table, to ensure every aspect of your project needs are met. PharmEng Technology is a multicultural company with staff all over the world servicing companies of all sizes. We are confident that we are the solution you need to operate in this highly regulated industry.

PharmEng Technology is one of the leading consulting firms in the world with offices in USA, Canada and Asia. We have developed a stable client base and provide services all around the world including USA, Canada, Asia, Europe, Australia and Africa.

China Resources Life Science Park

China Resources Life Science Park (CRLSP) is an ideal place for life science companies to establish innovation, R&D, and manufacturing facilities. It covers an area of over 100 acres, an existing constructional floor area of 1,000,000 m². As one of the key projects of CBR (China Bio-medicine Park) base.

CRLSP has leveraged national level research resources and its location right in the capital to turn itself into a world-class industry town. Within specially dedicated zone policy that enjoy a series of benefits from municipal, provincial and central governments. Companies can enjoy benefits like government-backed financing, tax breaks and grants for research and scientist. The one-stop shops are where, companies can combine suppliers, clients and the talent pool together.

By providing innovative incubator funds and professional service from CR group, CRLSP is trying to maximize the success possibilities of incubation.

CRLSP in the core of Beijing-Tianjin-Hebei Region

18.6 miles south of Tiananmen Square
1.86 miles to subway Line 4
12.4 miles to Beijing Daxing International Airport
48.4 miles direct to Zhangjiajie New Area
180.8 miles away from Tianjin Jin Port
Established in August 2015, Shanghai Furen Medicine R&D Co., Ltd. is a leading research and development center for new therapeutics and new medical technologies. The parent company of Shanghai Furen, Furen Medicines Group, is one of the top 50 pharmaceutical companies in China. Shanghai Furen has two campuses. Its Minhang Campus, which has 18,000 square meter (193,000 square feet) of offices and research laboratories, is located in DP-PARK, Lingang Pujiang International Science and Technology City. In addition, Shanghai Furen is building its Songjiang Campus, which will have 42,000 square meter (452,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics (large molecules), New Therapeutics (small molecules), Generics and Other Health Products.

As the strategic focus of Furen Medicines Group, Shanghai Furen has undertaken the important missions of promoting technology and management innovations, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantage in geography, talent, economy, transportation and innovative environment to build a world-class innovation center.

Address: 797 Puxing Rd, DP-PARK, Minhang District, Shanghai, China 201114
Website: http://www.shfmrd.com
E-mail: info@shfmrd.com
Telephone: 021-34731200
Fax: 021-34730110

Learn more at: CrownBio.com

Get Clarity With CrownBio
Our premier translational platforms for Oncology and Cardiovascular & Metabolic Disease help clients accelerate their new drug development programs.

CrownBio develops world-leading preclinical efficacy models and provides both in vitro and in vivo testing services and preclinical research products.

Learn more at: CrownBio.com

WE POWER ANTIBODY DISCOVERY

- Adagene was co-founded by two serial entrepreneurs, Rainer Lue and Gu Li, to power antibody discovery in China for the world market.
- Adagene is showcasing the power of its proprietary Dynamic Precisionfinity (DP) platform to accelerate multiple innovative therapeutic candidates into clinical trials around the world.
- Adagene is a well-financed, privately held company having successfully raised over $30 million from international VC groups.
- Adagene is based at a leading biotech park, Baidu, in Suzhou, China.
- We are building a global and talented team with highly respected and regarded scientists. Adagene is looking for entrepreneurial and driven multidisciplinary talent to join our team.

FOR MORE INFORMATION, PLEASE VISIT WWW.ADAGENE.COM.
Frontier Biotech Corporate Introduction

Frontier Biotechnologies Inc ("Frontier Biotech") is a China-based global biopharmaceutical company with core competence in developing novel anti-viral and long-acting drug products. Founded in 2002, Frontier Biotech has been dedicated in the discovery, development, manufacture and commercialization of innovative drug products targeting unmet clinical needs for the past 16 years. The management team has extensive business and development experience in pharma/biotech industry in US, China and Japan. Our mission is to become a science-driven biopharmaceutical company with global competitiveness and to develop innovative therapies for addressing unmet medical needs for patients and the society. Currently the company has three drug candidates in late-stage development.

Albuvirtide (ABT) is the first novel AIDS drug in China and the second long-acting AIDS drug in the world, with a novel molecular mechanism of action. Data from a phase 3 clinical trial illustrated that Albuvirtide was safe and effective against major strains of HIV including resistant viruses. An NDA has been filed to CFDA.

3BNC117 is a fully human broad spectrum HIV neutralizing monoclonal antibody (bNAb) licensed from The Rockefeller University. It is one of the best bNAbs and the most advanced in clinical development in the world. Frontier Biotech intends to combine Albuvirtide with 3BNC117 to form an all-injectable long-acting drug regimen for viral suppression and viral reservoir clearance.

AB001 is a third generation topical patch for pain management. A proof-of-concept phase 2 trial in patients with chronic low back pain was completed in the US, and endpoints were met with statistical significance.
Explore resources and technologies that support antibody therapeutics research and development through all stages of the pipeline.

We offer assays and tools for evaluating and characterizing mAbs in Fc effector assays, immune checkpoint assays, and antibody internalization studies.

Our product portfolio includes easy to use assays that can be used to build a comprehensive assessment of cell health in multiple model systems.

Contact: Sarah Theos | sarah.theos@promega.com
Company Introduction
I-Mab, led by a group of top-notch immunologists and drug developers in China and US, with the most innovative biologics R&D platform in China, is positioned as a global player to develop the First-in-Class and Best-in-Class biologics concentrating on the areas of immuno-oncology and immuno-inflammation.

Pipeline and Portfolio
I-Mab’s pipeline is comprised of two biologics portfolios and has a total of 16 innovative assets currently.

Applications

- **TCID50 assays**: Routine HIV infectivity & quantification
- **Anti-HIV drug screenings**: Via one-step infection
- **Routine EC50/LD50 quantifications**: Of anti-HIV compounds
- **Screenings for neutralizing antibodies**: (bnAB) (from laboratory and clinical research samples)
- **Neutralizing antibody quantifications**
- **HIV cell-to-cell transmission & HIV drug resistance studies**
- **Low-level HIV gene expression assessments**
- **HIV pre-integration transcription studies**
- **HIV latency and reactivation studies**
- **HIV outgrowth detection following reactivation**
- **HIV tropism determinations**

Are your current cells leaving you blue?
A new generation of HIV Reporter Cells

- **Unparalleled sensitivity & specificity**: Rev-regulated reporter
- **Versatile**: GFP & Luciferase dual reporter system
- **Natural HIV target**: Derived from Human CD4 T-cells
- **Physiologically relevant**: Natural levels of HIV receptors/coreceptors
- **Broad susceptibility**: Susceptible to X4, R5, primary HIV isolates, some SIV

Prior to infection, HIV(AD8), an R5 virus, was incubated with or without the HIV neutralizing antibody B12 (10 μg ml⁻¹ final). After 1 h, ViroVision™ Rev-A3R5-GFP cells were infected with Ab-neutralized and non-neutralized virus. Cells were washed and cultured for 48 hours. GFP expression was quantified by flow cytometry. PI = propidium iodide.
AN EXPERT CRO
expediting patient access to safety and efficacy clinical products

ACCELERATING PRODUCT DEVELOPMENT

<table>
<thead>
<tr>
<th>Products/Indications/Trials</th>
<th>Clinical Operations</th>
<th>Clinical Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Pharmaceuticals</td>
<td>• Protocol writing</td>
<td>• Clinical data management</td>
</tr>
<tr>
<td>• Biologics</td>
<td>• Project management</td>
<td>• Clinical trials &amp; sponsorships</td>
</tr>
<tr>
<td>• Pharmacovigilance</td>
<td>• Regulatory compliance</td>
<td>• Clinical support &amp; services</td>
</tr>
<tr>
<td>• Medical affairs</td>
<td>• Clinical drug development</td>
<td>• Clinical</td>
</tr>
</tbody>
</table>
SILVER

China Resources Pharmaceutical Co., Ltd. (“CR”) or China Resources Group, is a diversified holding company registered in Hong Kong. CR was first established as “Liow & Co.” in 1883, then the direct ancestor of SAGA, the forerunner of the key state-owned enterprises. China Resources Pharmaceutical Co., Ltd. is one of the Fortune Global 500 enterprises, ranking the 279th on the list of the largest Chinese business, because its brands and gas companies are the biggest in China. CR has been providing service to the international and domestic customers, service providers and business operations and operational efficiency. CR China is one of the most prominent and influential real estate developers in mainland China. CR PharmEngPharma, which relates to the Shanghai Subsidiary, a “white paper”, a “Continental granted water”, “CR Yinglang” supplementation, and the “CR” PET. CR is a Double Categories, R&D, 20% of the wine and alcohol in China.

Since the advent of the 21st century, CR has built a strong industrial foundation, and significantly increased its excellent competitive strength.

Pharmacy Technology has been providing quality services to the manufacturers of healthcare products for over 15 years. In highly regulated industries, there is a need for specialized professionals who can provide solutions on a cost-effective and diverse manner. Pharmacy Technology is a full service consulting from that offers government & Quality, Validations, Quality Systems, Regulatory Affairs, Engineering and Training. We provide a wide range of services to the pharmaceutical, biotechnology, medical device and animal health industry. We are a global company and we are here to assist any company with your unique business challenges.

Pharmacy Technology, we have highly qualified and dedicated professionals who deliver quality services at any facility or around the world. Our pharmaceuticals technical services on the regulatory and validation, and the excellent reference from the global market to establish, to ensure every aspect of your project needs are met. Pharmacy Technology is a multidisciplinary company with staff all over the world serving companies of all sizes. We are confident that we can provide you with a service in the highly regulated industry.

Waters Corp. is a publicly traded corporation (NYSE:WAT) headquartered in Milford, Massachusetts, USA, with worldwide locations on complementary analytical technologies. With over 8,000 employees, our staff includes more than 1,000 Ph.D. scientists and engineers in the United States. A leader in vaccine development and adult stem cell production, Maryland is home to one of the largest academic research institutions in the world.

Established in August 2016, Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Established in August 2016, Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.

Shanghai Furen Medicine & Co., Ltd. is a leading research and development company for the new biopharmaceuticals and the new medical technologies. The parent company of Shanghai Furen Medicine & Co., Ltd. is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two companies. In Wuhan City, which has 10,000 square meters (100,000 square feet) of offices and research laboratories, is located in ORH, employing Panhan International Corporation and the West China City. In addition, Shanghai Furen is a branch company of Shanghai, which have 4,000 square meters (150,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics, Rare Diseases, Other Health Products, the strategic drug of Off-Market Medicine Group. Shanghai Furen has undertaken the important mission of promoting new drug development and improved specialized, and opening up new growth paths. Shanghai Furen is using Shanghai’s unique advantages in geography, economic, technology, business environment and innovation to build a world-class innovation center.
Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

**SPONSOR HIGHLIGHTS**

**ORIGENE**

OmniScriptum Technology, Inc. is a go-to resource for gene function studies. Founded in 1994, headquartered in Rockville, MD, OmniScriptum has branches in China and Germany. OmniScriptum’s gene-centric tools is built for high-throughput, including:

1. cDNA expression plasmids/lentivectors
2. Antibodies and Resins
3. Recombinant Proteins
4. OIPREX vector/Novel RNAi

For more information, visit www.omniscriptum.com.

**Kirin**

Peptron’s solution gives you lab verification from drug discovery with biology, and small molecule portfolio to a portfolio of vary easy to use, and practicality, for a comprehensive assessment of cell health trait. No matter what lab you are in on Peptron’s has the tools for you to be successful in your research. Stop by our table while at the CBA Annual Conference to learn more about the lab you can work with you.

**Adagene**

Adagene (Shenzhen) is an innovative antibody engineering and discovery company for global unmet medical needs. Using its proprietary Dynamic Protein Display Platform (DPDP), Adagene is developing diverse-accessible antibodies against novel epitopes that give unique product profiles that have potential to succeed where others have failed.

Adagene is leveraging its exceptional antibody engineering capabilities by building a portfolio of products with multiple specificities that are across species, in oncology, and in infectious diseases. Our mission is to bring innovative antibody therapeutics to patients in need with potential to succeed where others have failed.

Adagene's lead product is Fylogin® (binds in the ESI, BSA, and CBA in 2018) which exhibits robust single agent and combination activity in multiple pre-clinical models. Also, Adagene’s second and third products are currently in filing global INDs in 2018 and 2020. The company’s management team is composed of industry veterans with proven track record in antibody drug discovery and development. We are committed to delivering porfits to our clients’ success.

We are pleased to be invited to this conference as part of the Biotec Group, and we look forward to meeting some of you in the coming days.

**Diego, CA is now operating under an ISO 13485:2003 certified quality management system.**

**Promega**

Promega has been a leader in providing lab validation from drug discovery with biology, and small molecule portfolio to a portfolio of vary easy to use, and practicality, for a comprehensive assessment of cell health trait. No matter what lab you are in on Promega’s has the tools for you to be successful in your research. Stop by our table while at the CBA Annual Conference to learn more about the lab you can work with you.

**Kelun Group**

Kelun Group’s revenues in 2015 exceeded RMB 39 billion, or USD 6 billion. Kelun Pharmaceutical is committed to R&D for small-molecule NCEs and biological therapeutic products. Kelun Group has over 30 years of experience in the development of innovative medicines, and Kelun has successfully completed numerous development projects in China and internationally. Kelun Group is recognized as a top-tier pharmaceutical company in China.

**CBA**

The company’s management team is composed of industry veterans with proven track record in antibody drug discovery and development. We are committed to delivering porfits to our clients’ success.

We are pleased to be invited to this conference as part of the Biotec Group, and we look forward to meeting some of you in the coming days.

**Biogen**

Biogen is a biotechnology company with a global presence in the development and production of innovative medicines for the treatment of serious, life-threatening and chronic medical conditions. Biogen’s portfolio includes marketed medicinal products, drug candidates under development and an extensive research pipeline.

**Kiran**

The Kiran Cancer Foundation was established in 1998 as a non-profit organization (NPO) that engages in scientific research and public awareness to fight wasting diseases, including HIV/AIDS.

**Baltugen**

Baltugen develops high-relocating, world-class antibiotics, recombinant proteins, and biologics manufactured at our facilities in San Diego. Our mission is to create therapeutic products and discoveries that will bring relief to patients suffering from life-threatening and serious diseases.

**Metabio**

Metabio is a leader in the growing field of metabolomics, the study of small molecules in the body. Metabio offers a comprehensive suite of services to help you understand the role of metabolic pathways in health and disease.

**BioLegend**

Biologics is a global leader in the design, development, and manufacture of recombinant proteins and antibodies for research and diagnostic laboratories.

**CBA**

The company’s management team is composed of industry veterans with proven track record in antibody drug discovery and development. We are committed to delivering porfits to our clients’ success.

We are pleased to be invited to this conference as part of the Biotec Group, and we look forward to meeting some of you in the coming days.

**I-Mab Biopharma**

I-Mab Biopharma was formed by a 2017 merger between Three Nucleus Biotech (founded by Dr. Jingwu Zang, Tigermed and Baxalta) and Tangle Bio (founded by Dr. Jingwu Zang). Tangle Bio is a leading biotech company in China with a focus on therapeutic antibodies and a strong pipeline of innovative products in oncology.

**PCR® Machine**

PCR® Machine is a leading provider of PCR products and services. PCR® Machine has been in operation since 1983 and is headquartered in Shenzhen, China. PCR® Machine offers a wide range of PCR products, including Taq polymerases, dNTPs, PCR primers, and other PCR-related reagents.

**Promega**

Promega has been a leader in providing lab validation from drug discovery with biology, and small molecule portfolio to a portfolio of vary easy to use, and practicality, for a comprehensive assessment of cell health trait. No matter what lab you are in on Promega’s has the tools for you to be successful in your research. Stop by our table while at the CBA Annual Conference to learn more about the lab you can work with you.

**ATCS**

ATCS was founded in December 2005 in Beijing, Suchia Sinegrine Industrial Park, Suchia, China, by Dr. Nanhai Li who is a distinguished scientist with over 30 years worked in the field of hematological science both in the US and China. ATCS has been honored by the Chinese government as a highly influential international medical institution. The R&D team at ATCS, led by Dr. Nanhai Li, Zhang Xing and Wu, has been tested on natural killer cell (NK) & T-cell platforms in developing over 30 CAR T-cell therapy products. ATCS has the relevant technologies and capabilities to develop different types of therapeutics. The preclinical clinical research studies have shown that ATCS CAR NK therapy holds a remarkable response rate and partly persistent remission in the treatment of over 80% solid tumors including but not limited to breast cancer, lung cancer, renal cancer, and pancreatic cancer. ATCS has been well-positioned in the fast-growing tumor immunotherapeutics field with the proprietary CAR NK technology.

**CBA**

The company’s management team is composed of industry veterans with proven track record in antibody drug discovery and development. We are committed to delivering porfits to our clients’ success.

We are pleased to be invited to this conference as part of the Biotec Group, and we look forward to meeting some of you in the coming days.

**Promega**

Promega has been a leader in providing lab validation from drug discovery with biology, and small molecule portfolio to a portfolio of vary easy to use, and practicality, for a comprehensive assessment of cell health trait. No matter what lab you are in on Promega’s has the tools for you to be successful in your research. Stop by our table while at the CBA Annual Conference to learn more about the lab you can work with you.

**ATCS**

ATCS was founded in December 2005 in Beijing, Suchia Sinegrine Industrial Park, Suchia, China, by Dr. Nanhai Li who is a distinguished scientist with over 30 years worked in the field of hematological science both in the US and China. ATCS has been honored by the Chinese government as a highly influential international medical institution. The R&D team at ATCS, led by Dr. Nanhai Li, Zhang Xing and Wu, has been tested on natural killer cell (NK) & T-cell platforms in developing over 30 CAR T-cell therapy products. ATCS has the relevant technologies and capabilities to develop different types of therapeutics. The preclinical clinical research studies have shown that ATCS CAR NK therapy holds a remarkable response rate and partly persistent remission in the treatment of over 80% solid tumors including but not limited to breast cancer, lung cancer, renal cancer, and pancreatic cancer. ATCS has been well-positioned in the fast-growing tumor immunotherapeutics field with the proprietary CAR NK technology.
Guangzhou Biotech Industry Organization is an alliance supervised and supported by the Guangzhou government, together with the lead of joint Guangzhou bio-tech enterprises, and founded in 2011 after the authorization by Bureau of City Affairs of Guangzhou Municipality. The organization now owns more than 120 memberships, including bio-pharmaceutical enterprises, colleges and research institutions, medical institutions, investment organizations and other associations.

The organization is giving full use of available facilities and advantages, following the purpose of ‘Combining leading enterprise, assembling quality enterprises, introducing supportive funding, accelerating clinical alternation, sharing the organization and improving the development of the industry.’ Meanwhile, talent group will be formed by the expert academics from domestic and international-wide in the organization, which follows the path of innovative combination for both industry-capital and fund capital, and be committed to build an efficient platform of rapid development and improvement for Guangzhou bio-tech companies. It will concentrate on the enquiries of the industry development, with proper guidance and support from government, increasing social inclusion and capitalized operation to promote the connection and integration of market resources, which finally lead to a completed loop of collaborative development, and take the load of Guangzhou bio-tech industry.

SPONSOR HIGHLIGHTS

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA 2018 FULL CONFERENCE AGENDA AT-A-GLANCE

7:30-8:30 | Registration and Continental Breakfast; Exhibition Booth Setup
7:30-8:30 | Welcome to CBA’s 23rd Annual Conference
8:30-8:50 | Opening Remarks
8:50-8:55 | Introduction of CBA Brilliant Achievement Award: Lucy Chen, M.D., Ph.D.
9:20-9:25 | Introduction of CBA Brilliant Achievement Award: Richard Pazdur, MD
9:25-9:50 | CBA Brilliant Achievement Award Presentation: 1979-2016: Personal Reflections on Nixon’s War on Cancer
9:50-10:00 | Coffee Break
10:00-10:05 | Introduction of CBA Brilliant Achievement Award: Guangqiao Li, M.D., Ph.D.
10:05-10:30 | CBA Brilliant Achievement Award Presentation: Follow the Science and Capture the Opportunity
10:30-10:35 | Introduction of CBA Brilliant Achievement Awards: Laurence J.K. Cooper, M.D., Ph.D.
10:35-11:00 | CBA Brilliant Achievement Award Presentation: The Genetic Engineering of T Cells: From Bench, To Bedside, to Boardroom
11:00-11:05 | Panel Discussion
11:10-11:35 | Special Presentation by Miki: Creating the Pharmaceutical Innovation Ecosystem
11:35-12:00 | Global Drug Development: ICR and Role of China
12:00-12:25 | CBA’s Regulatory Reform: Opportunities and Challenges
12:25-12:35 | Panel Discussion
12:35-1:30 | Lunch

1:30-2:30 | PARALLEL SESSION A: Entrepreneur Incubators and Collaboration - Auditorium
1:30-1:45 | Incubators in Montgomery County, MD
1:45-2:15 | Incubators in China
2:15-2:25 | Introduction of Maryland International Incubator
2:25-3:20 | Panel Discussion
3:20-3:30 | Artifical Intelligence and Big Data in Biopharmaceutical Development - Auditorium
2:30-2:50 | Application of Deep Learning in Drug Discovery
2:50-3:10 | Burn the Haystack: Finding the Needle in Clinical Notes & Genomics at Scale
3:10-3:30 | Deep Learning Convolutional Neural Networks Techniques & Their Applications in Biomedical Sciences - A Successful Example in Lung Imaging
3:30-4:00 | Break
3:40-5:00 | Entrepreneurs and Investors
3:40-3:50 | Proprietary Technologies to Produce the Most Generation Growth Factors in Green Algae
3:50-4:00 | Immunotherapy for Solid Tumors by Chimeric Antigen Receptor (CAR)-Modified Macrophages (MAC) Cells
4:00-4:10 | Nanoelectrode for Fast Manufacturing of CAR-T Cells
4:10-4:20 | Stimulation of Gamma Delta T Cells for Treatment of Epithelial Solid Tumors
4:20-4:30 | Targeted and Personalized Peptide Therapy - ISSA & PHS05 in Prostate Cancer
4:30-4:40 | Building a China Biopharmaceuticals with Distinguished Team-Pipeline and Portfolio
4:40-4:50 | Panel Discussion

4:50-6:30 | CEO Roundtable
6:30-7:15 | Reception
7:15-8:45 | Dinner Banquet
8:30-9:20 | Opening Remarks by MC
7:25-8:40 | NIH-CSSA Prize Drawings, Speech, Entertainment, Performance
7:25-8:45 | Conclusion Remarks
8:00 | Conference / Event Concludes